scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed$ 125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at ...